aspirin has been researched along with Nervous System Disorders in 39 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States." | 9.27 | Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 9.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 9.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States." | 5.27 | Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 5.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months." | 5.19 | Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "Among 603 patients recruited, 353 patients(180 treated with LMWH, 173 with aspirin) had acute ischemic stroke and LAOD." | 5.16 | Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, Q; Wong, KS, 2012) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 5.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| " The combination of heparin and low-dose aspirin is effective in significantly increasing the chances of a successful pregnancy in woman with recurrent pregnancy failure associated with antiphospholipid antibodies." | 4.81 | Treatment of the antiphospholipid syndrome. ( Roubey, RA, 2002) |
| "A total of 85 patients with acute ischemic stroke on 160mg aspirin daily were prospectively included." | 3.77 | Aspirin non-responder status and early neurological deterioration: a prospective study. ( Bugnicourt, JM; Canaple, S; Garcia, PY; Godefroy, O; Lamy, C; Roussel, B, 2011) |
| " Oral administration of ticlopidine inhibited the transient thrombocytopenia caused by ADP." | 3.66 | Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP. ( Butler, KD; White, AM, 1980) |
| "Aspirin was fully efficient in only 30% of cases." | 2.76 | Neurological disorders in essential thrombocythemia. ( Billot, S; Carpentier, AF; Cassinat, B; Fenaux, P; Jardin, C; Kiladjian, JJ; Kouroupi, EG; Laperche, T; Le Guilloux, J, 2011) |
| "The diagnosis of Reye's syndrome is not straightforward, as the symptoms are very diverse." | 2.47 | [The Reye syndrome]. ( Duh, D; Tanret, I, 2011) |
| "Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| "Nimodipine and aspirin were set as positive control separately." | 1.43 | Sodium Sulfide, a Hydrogen Sulfide-Releasing Molecule, Attenuates Acute Cerebral Ischemia in Rats. ( Chen, B; Cheng, MH; Fan, BS; Shi, HQ; Tian, JS; Yu, JG; Zhang, Y, 2016) |
| "Macrophage density in carotid artery plaques classified by B-mode ultrasound imaging as echolucent (n = 56), intermediate (n = 25), or echorich (n = 25) was 1." | 1.31 | Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. ( Bentzon, J; Falk, E; Grønholdt, ML; Nordestgaard, BG; Sillesen, H; Wiebe, BM; Zhou, J, 2002) |
| " While steroid dosage was gradually decreased, administration of acetylsalicylic acid (for three months 100 mg daily, then three times daily 100 mg) brought about complete disappearance of the visual signs." | 1.28 | [The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities]. ( Berg, PA; Leo-Kottler, B; Weller, M; Wiethölter, H, 1991) |
| "20 patients with thrombotic thrombocytopenic purpura (TTP) admitted to the Mt." | 1.26 | Thrombotic thrombocytopenic purpura: a ten-year experience. ( Cuttner, J, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (23.08) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 5 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, JX | 1 |
| Ma, WJ | 1 |
| He, LY | 1 |
| Zhang, CH | 1 |
| Zhang, C | 1 |
| Wang, Y | 1 |
| Chen, CN | 1 |
| Shen, DY | 1 |
| Gao, HM | 1 |
| Guo, RR | 1 |
| Ning, QQ | 1 |
| Ye, XC | 1 |
| Cui, GY | 1 |
| Li, L | 1 |
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Zhong, J | 1 |
| Gao, Y | 1 |
| Huang, D | 1 |
| Hu, Y | 2 |
| He, Q | 1 |
| Diao, L | 1 |
| Chen, W | 1 |
| Mueller, AA | 1 |
| Vaidya, A | 1 |
| Tarter, LL | 1 |
| Klein, JP | 1 |
| Barkoudah, E | 1 |
| Cherqaoui, B | 1 |
| Koné-Paut, I | 1 |
| Yager, H | 1 |
| Bourgeois, FL | 1 |
| Piram, M | 1 |
| Khatri, P | 1 |
| Kleindorfer, DO | 1 |
| Devlin, T | 1 |
| Sawyer, RN | 1 |
| Starr, M | 1 |
| Mejilla, J | 1 |
| Broderick, J | 1 |
| Chatterjee, A | 1 |
| Jauch, EC | 1 |
| Levine, SR | 1 |
| Romano, JG | 1 |
| Saver, JL | 1 |
| Vagal, A | 1 |
| Purdon, B | 1 |
| Devenport, J | 1 |
| Pavlov, A | 1 |
| Yeatts, SD | 1 |
| Surnar, B | 1 |
| Kolishetti, N | 1 |
| Basu, U | 1 |
| Ahmad, A | 1 |
| Goka, E | 1 |
| Marples, B | 1 |
| Kolb, D | 1 |
| Lippman, ME | 1 |
| Dhar, S | 1 |
| Cheng, F | 1 |
| Li, W | 1 |
| Zhou, Y | 1 |
| Li, J | 1 |
| Shen, J | 1 |
| Lee, PW | 1 |
| Tang, Y | 1 |
| Yi, X | 3 |
| Lin, J | 3 |
| Wang, C | 3 |
| Zhang, B | 2 |
| Chi, W | 1 |
| Wang, Z | 1 |
| Huang, W | 1 |
| Zuo, Z | 1 |
| Liao, D | 1 |
| Chi, L | 1 |
| Park, JH | 1 |
| Ovbiagele, B | 1 |
| Shi, HQ | 1 |
| Zhang, Y | 1 |
| Cheng, MH | 1 |
| Fan, BS | 1 |
| Tian, JS | 1 |
| Yu, JG | 1 |
| Chen, B | 1 |
| Liu, P | 1 |
| Fu, C | 1 |
| Chen, Y | 1 |
| Field-Fote, EC | 1 |
| Bugnicourt, JM | 1 |
| Roussel, B | 1 |
| Garcia, PY | 1 |
| Canaple, S | 1 |
| Lamy, C | 1 |
| Godefroy, O | 1 |
| Tanret, I | 1 |
| Duh, D | 1 |
| Comi, AM | 1 |
| Billot, S | 1 |
| Kouroupi, EG | 1 |
| Le Guilloux, J | 1 |
| Cassinat, B | 1 |
| Jardin, C | 1 |
| Laperche, T | 1 |
| Fenaux, P | 1 |
| Carpentier, AF | 1 |
| Kiladjian, JJ | 1 |
| Fiorella, D | 1 |
| Wang, Q | 1 |
| Chen, C | 1 |
| Chen, XY | 1 |
| Han, JH | 1 |
| Soo, Y | 1 |
| Leung, TW | 1 |
| Mok, V | 1 |
| Wong, KS | 1 |
| Froehler, MT | 1 |
| PARIS, L | 1 |
| NEWFIELD, H | 1 |
| van den Bergh, WM | 1 |
| Algra, A | 1 |
| Dorhout Mees, SM | 1 |
| van Kooten, F | 1 |
| Dirven, CM | 1 |
| van Gijn, J | 1 |
| Vermeulen, M | 1 |
| Rinkel, GJ | 1 |
| Cuttner, J | 1 |
| Vargha von Szeged, A | 1 |
| Michos, N | 1 |
| Butler, KD | 1 |
| White, AM | 1 |
| Tomlin, P | 1 |
| Newton, R | 1 |
| Michiels, JJ | 1 |
| Koudstaal, PJ | 1 |
| Mulder, AH | 1 |
| van Vliet, HH | 1 |
| Sánchez García, P | 1 |
| Pauzner, R | 1 |
| Dulitzki, M | 1 |
| Langevitz, P | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Many, A | 1 |
| Grønholdt, ML | 1 |
| Nordestgaard, BG | 1 |
| Bentzon, J | 1 |
| Wiebe, BM | 1 |
| Zhou, J | 1 |
| Falk, E | 1 |
| Sillesen, H | 1 |
| Roubey, RA | 1 |
| Hollister, LE | 1 |
| Preston, FE | 1 |
| Martin, JF | 1 |
| Stewart, RM | 1 |
| Davies-Jones, GA | 1 |
| Ross, WF | 1 |
| Pearson, JM | 1 |
| Weller, M | 1 |
| Leo-Kottler, B | 1 |
| Berg, PA | 1 |
| Wiethölter, H | 1 |
| Dickey, W | 1 |
| Morrow, JI | 1 |
| Kolodny, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)[NCT02072226] | Phase 3 | 313 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to The study was terminated due to slow enrollment.) | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reported here is the percentage of participants who died due to any cause during the study. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 0.6 |
| Alteplase Placebo + Aspirin | 0 |
Reported here is the percentage of participants who died due to stroke and neurological disorders. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 0 |
| Alteplase Placebo + Aspirin | 0 |
mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 78.2 |
| Alteplase Placebo + Aspirin | 81.5 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02072226)
Timeframe: From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90.
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 77.3 |
| Alteplase Placebo + Aspirin | 68.0 |
A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 26.0 |
| Alteplase Placebo + Aspirin | 13.1 |
ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 3.2 |
| Alteplase Placebo + Aspirin | 0 |
mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| mRS at Day 90 - 0 | mRS at Day 90 - 1 | mRS at Day 90 - 2 | mRS at Day 90 - 3 | mRS at Day 90 - 4 | mRS at Day 90 - 5 or 6 (death) | |
| Alteplase + Aspirin Placebo | 44.9 | 33.3 | 11.5 | 2.6 | 5.1 | 2.6 |
| Alteplase Placebo + Aspirin | 50.3 | 31.2 | 11.5 | 3.2 | 2.5 | 1.3 |
To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any ICH within 36 hours reported by site | Any ICH within 36 hours reported by central reader | |
| Alteplase + Aspirin Placebo | 7.1 | 7.1 |
| Alteplase Placebo + Aspirin | 2.6 | 3.3 |
Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index [BI] greater than or equal to 95, and Glasgow Outcome Scale [GOS] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| mRS 0 - 1 at Day 90 | NIHSS 0 - 1 at Day 90 | BI >= 95 at Day 90 | GOS = 1 at Day 90 | |
| Alteplase + Aspirin Placebo | 78.2 | 85.0 | 79.3 | 81.5 |
| Alteplase Placebo + Aspirin | 81.5 | 81.7 | 88.7 | 85.6 |
7 reviews available for aspirin and Nervous System Disorders
| Article | Year |
|---|---|
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review.
Topics: Adolescent; Aspirin; C-Reactive Protein; Case-Control Studies; Child; Child, Preschool; Coronary Dis | 2021 |
[The Reye syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Humans; Nervous System Diseases; Prognosis; | 2011 |
Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Brain; Diagnosis, Differential; D | 2011 |
Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Nervous System Diseases; Neuroprotective Agents; | 2010 |
Treatment of the antiphospholipid syndrome.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Humans; Nerv | 2002 |
Effective use of analgesic drugs.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ast | 1976 |
Drug-induced neurological disorders.
Topics: Antihypertensive Agents; Aspirin; Brain Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Nervou | 1990 |
9 trials available for aspirin and Nervous System Disorders
| Article | Year |
|---|---|
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aspirin; Bayes Theorem; Brain Ischemia; Dou | 2018 |
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male; | 2014 |
Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke.
Topics: Acute Disease; Aged; Aspirin; Atherosclerosis; Clopidogrel; Female; Humans; Male; Nervous System Dis | 2015 |
Neurological disorders in essential thrombocythemia.
Topics: Amino Acid Substitution; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; H | 2011 |
Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease.
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Chi-Square Distribution; Drug Administra | 2012 |
Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study.
Topics: Aneurysm, Ruptured; Aspirin; Drug Administration Schedule; Female; Humans; Intracranial Aneurysm; Ma | 2006 |
[Experience with suprofen for acute and chronic pain in neurologic practice].
Topics: Acute Disease; Adult; Aspirin; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug | 1983 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth | 1988 |
23 other studies available for aspirin and Nervous System Disorders
| Article | Year |
|---|---|
Macrophage migration inhibitory factor (MIF) acetylation protects neurons from ischemic injury.
Topics: Acetylation; Animals; Aspirin; Histone Deacetylase 6; Humans; Intramolecular Oxidoreductases; Ischem | 2022 |
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
Analysis of antiplatelet therapy adherence in patients with ischemic cerebral stroke.
Topics: Aspirin; Humans; Ischemic Stroke; Medication Adherence; Nervous System Diseases; Platelet Aggregatio | 2023 |
Caught in a Flare.
Topics: Arthralgia; Aspirin; Atorvastatin; Brain; Diagnosis, Differential; Exanthema; Fatigue; Female; Hemat | 2020 |
Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Cell Pr | 2018 |
Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs).
Topics: Arrhythmias, Cardiac; Aspirin; Benzhydryl Compounds; Bradycardia; Computer Simulation; Databases, Ch | 2013 |
Perioperative aspirin improves neurological outcome after focal brain ischemia possibly via inhibition of Notch 1 in rat.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Infarction; D | 2014 |
Neurologic symptom severity after a recent noncardioembolic stroke and recurrent vascular risk.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Double-Blind Method; Female; Fibri | 2015 |
Sodium Sulfide, a Hydrogen Sulfide-Releasing Molecule, Attenuates Acute Cerebral Ischemia in Rats.
Topics: Acute Disease; Analysis of Variance; Animals; Apoptosis; Aspirin; Blood Pressure; Cell Survival; Cel | 2016 |
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M | 2016 |
Does the dose do it?
Topics: Arterial Occlusive Diseases; Aspirin; Exercise; Guidelines as Topic; Humans; Nervous System Diseases | 2009 |
Aspirin non-responder status and early neurological deterioration: a prospective study.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle Aged; N | 2011 |
Successful treatment of cerebral venous sinus thrombosis with the Solitaire FR thrombectomy device.
Topics: Anticoagulants; Aspirin; Cerebral Angiography; Endovascular Procedures; Female; Follow-Up Studies; H | 2013 |
MORNING STIFFNESS IN ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Humans; Joint Diseases; Nervous System Diseases; Placebos | 1963 |
Thrombotic thrombocytopenic purpura: a ten-year experience.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aspirin; Dextrans; Dipyridamole; Female; Heparin; | 1980 |
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen | 1980 |
Blood platelets and neurological dysfunction.
Topics: Aspirin; Blood Platelets; Child; Dipyridamole; Humans; Ischemic Attack, Transient; Migraine Disorder | 1982 |
Transient neurologic and ocular manifestations in primary thrombocythemia.
Topics: Adult; Aged; Aspirin; Eye Diseases; Female; Humans; Male; Middle Aged; Nervous System Diseases; Plat | 1993 |
[A 100 years of aspirin: a drug with a future?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Di | 1997 |
Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels.
Topics: Analysis of Variance; Aspirin; Carotid Arteries; Carotid Artery Diseases; Carotid Stenosis; Endarter | 2002 |
Thrombocytosis, circulating platelet aggregates, and neurological dysfunction.
Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelet Disorders; Child; Dipyridamole; Drug Therapy, Combi | 1979 |
The recognition and management of nerve damage under field conditions.
Topics: Aspirin; Humans; Leprosy; Nervous System Diseases; Prednisolone | 1975 |
[The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities].
Topics: Adult; Antibodies; Antiphospholipid Syndrome; Aspirin; Blindness; Female; Humans; Nervous System Dis | 1991 |